Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction.
- Published In:
- Expert opinion on investigational drugs, 33(12), 1167-1176 (2024)
- Authors:
- Kaya, Eda, Yilmaz, Yusuf, Alkhouri, Naim(4)
- Database ID:
- RPEP-08532
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-08532APA
Kaya, Eda; Yilmaz, Yusuf; Alkhouri, Naim. (2024). Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction.. Expert opinion on investigational drugs, 33(12), 1167-1176. https://doi.org/10.1080/13543784.2024.2441865
MLA
Kaya, Eda, et al. "Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction.." Expert opinion on investigational drugs, 2024. https://doi.org/10.1080/13543784.2024.2441865
RethinkPeptides
RethinkPeptides Research Database. "Survodutide in MASH: bridging the gap between hepatic and sy..." RPEP-08532. Retrieved from https://rethinkpeptides.com/research/kaya-2024-survodutide-in-mash-bridging
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.